Budget Amount *help |
¥22,880,000 (Direct Cost: ¥17,600,000、Indirect Cost: ¥5,280,000)
Fiscal Year 2019: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2018: ¥6,110,000 (Direct Cost: ¥4,700,000、Indirect Cost: ¥1,410,000)
Fiscal Year 2017: ¥11,700,000 (Direct Cost: ¥9,000,000、Indirect Cost: ¥2,700,000)
|
Outline of Final Research Achievements |
Genome editing is a biotechnology that can disrupt, repair and insert genes of interest and can be applied for fundamental treatment of various hereditary diseases. Development of nanotechnology capable of efficient delivery of genome editing factors is important for medical application. In this study, lipid nanoparticles that deliver CRISPR-Cas protein-gRNA complexes efficiently were developed. From a viewpoint of practical application, microfluidic device-based synthesizing methodology that enables seamless manufacturing scale-up was developed.
|